Angelini Pharma acquires Catalyst Pharmaceuticals for 3.5 billion euros
The Italian pharmaceutical giant Angelini Pharma, part of the Angelini Industries group, has officially announced the acquisition of the US-based company Catalyst Pharmaceuticals. The transaction has a total value of 3.5 billion euros, marking a fundamental strategic step for the Italian company's international expansion.
Catalyst Pharmaceuticals, listed on the Nasdaq, is a well-known entity in the biotech sector for developing therapies for rare diseases. Through this agreement, Angelini Pharma aims to strengthen its position in the global market by integrating new advanced therapeutic solutions into its portfolio.
This acquisition represents one of the most significant investments in recent years for an Italian pharmaceutical company. The primary objective is to combine the research and development expertise of both companies to improve access to medication for patients suffering from rare neurological conditions.
The operation has been met with interest by industry analysts, who see this move as a clear growth strategy for Angelini Industries. The Italian group thus confirms its commitment to competing at the highest international levels, focusing on scientific innovation and an increasingly solid presence in the United States.